Psoriasis Plays a Wild CARD

Nuffel, Elien Van; Afonina, Inna S.; Beyaert, Rudi

doi:10.1016/j.jid.2018.05.001

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not surprising given the overlapping genetics of PRP and psoriasis, including CARD14 mutations, which are associated with familial and sporadic PRP and induce psoriasiform skin inflammation in mice mediated by the IL-23/IL-17 pathway. 25,26 One PRP patient in our cohort had a confirmed CARD14 mutation and improved with ustekinumab. 24 These data indicate that IL-36 staining cannot be used to differentiate between PRP and psoriasis in cases with overlapping histopathologic features.…”

Section: Discussionmentioning

confidence: 88%

Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis‐like histopathologic features

Aquino

Calvarido

North³

2021

J Cutan Pathol

View full text Add to dashboard Cite

Background: Elevated epidermal interleukin (IL)-36 expression distinguishes psoriasis from eczematous dermatitis, but other psoriasiform dermatitides (PDs) have not been thoroughly investigated for IL-36 expression. In this study, we assess the IL-36 staining pattern (IL36-SP) in psoriasis variants and other PDs including lichen simplex chronicus (LSC), prurigo nodularis (PN), lichen planus (LP), tinea, pityriasis rubra pilaris (PRP), mycosis fungoides (MF), pemphigus foliaceus (PF), acute generalized exanthematous pustulosis (AGEP), impetigo (IMP), and syphilis (SY).Methods: IL-36 immunostaining was performed on 307 cases of psoriasis and various PDs. IL36-SP in the upper epidermis was graded on a scale of 0-4.Results: High IL36-SP occurred in all variants of psoriasis, as well as in AGEP, PRP, PN, tinea, IMP, and LP (P > 0.05). SY, PF, LSC, and MF showed a lower IL36-SP (P ≤ 0.05) compared with psoriasis. Conclusion:All variants of psoriasis exhibit high IL36-SP. IL-36 staining can assist in differentiating MF, PF, SY, and LSC from psoriasis, particularly MF and LSC, which have consistent low IL-36 expression. AGEP, PRP, tinea, IMP, PN, and LP exhibit high IL-36 expression similar to psoriasis, indicating Th17 activation in these diseases.

show abstract

Section: Discussionmentioning

confidence: 88%

Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis‐like histopathologic features

Aquino

Calvarido

North³

2021

J Cutan Pathol

View full text Add to dashboard Cite

show abstract

“…Previously, the association of CARD14 variants with psoriasis was reported in Japanese [ 33 ], Spanish [ 34 ], European [ 35 ], Chinese [ 31 , 32 , 36 , 37 ], and Tunisian [ 38 ] populations. Mechanistically, the mutations in the CARD14 gene lead to hyperinflammation in the keratinocytes, which causes immune cell infiltration, hyperproliferation of keratinocytes, and keratosis, which are typical hallmarks of psoriasis [ 39 ]. An in vivo study by Mellett et al [ 40 ] provided significant insights into the disease mechanism driven by CARD14 gain of function mutations.…”

Section: Discussionmentioning

confidence: 99%

Association of CARD14 Single-Nucleotide Polymorphisms with Psoriasis

Suleman

Chhabra

Raza

et al. 2022

IJMS

View full text Add to dashboard Cite

Psoriasis is an immune-mediated chronic and painful disease characterized by red raised patches of inflamed skin that may have desquamation, silvery-white scales, itching and cracks. The susceptibility of developing psoriasis depends on multiple factors, with a complex interplay between genetic and environmental factors. Studies have suggested an association between autosomal dominant CARD14 (caspase recruitment domain-containing protein 14) gain-of-function mutations with the pathophysiology of psoriasis. In this study, non-synonymous single-nucleotide polymorphisms (nsSNPs) of CARD14 gene were assessed to determine their association with psoriasis in Pakistani population. A total of 123 subjects (63 patients with psoriasis and 60 normal controls) were included in this study. DNA was extracted from blood, and PCR analysis was performed followed by Sanger sequencing for 18 CARD14 specific nsSNPs (14 previously reported and the 4 most pathogenic nsSNPs identified using bioinformatics analysis). Among the 18 tested SNPs, only 2 nsSNP, rs2066965 (R547S) and rs34367357 (V585I), were found to be associated with psoriasis. Furthermore, rs2066965 heterozygous genotype was found to be more prevalent in patients with joint pain. Additionally, the 3D structure of CARD14 protein was predicted using alpha-fold2. NMSim web server was used to perform coarse grind simulations of wild-type CARD14 and two mutated structures. R547S increases protein flexibility, whereas V353I is shown to promote CARD14-induced NF-kappa B activation. This study confirms the association between two CARD14 nsSNPs, rs2066965 and rs34367357 with psoriasis in a Pakistani population, and could be helpful in identifying the role of CARD14 gene variants as potential genetic markers in patients with psoriasis.

show abstract

“…Psoriasis has evolved conceptually over time, from being considered a skin disease in its first descriptions, currently we can define it as a chronic and inflammatory skin disease, without a defined, genetically determined, pathophysiologically autoimmune etiology, of intermittent evolution, at risk of skin, systemic and psychological comorbidities, which impact on quality of life [1]. The most characteristic feature of psoriasis is the hyperproliferation and altered differentiation of keratinocytes, in addition to immune, biochemical, and vascular abnormalities influenced by multiple environmental factors that can trigger or exacerbate its evolution, affecting between 2 and 3% of the population.…”

Section: Introductionmentioning

confidence: 99%

Comparative Stratification of Cardiovascular Risk through Framingham and Globo Risk in Patients with Psoriasis of IAHULA November 2017-May 2018

Sampayo¹,

Sarmiento²,

Cazorla³

et al. 2020

ACR

View full text Add to dashboard Cite

Objectives: To know the frequency of Metabolic Syndrome in patients with Psoriasis who come to the consultation of the Dermatology Service of the Autonomous University Hospital of the Andes November 2017 to May 2018. Materials and Methods:Observational analytical descriptive study. Patients with Psoriasis diagnoses who attended the dermatology office were selected, PASI, ATP-III, Framingham and GLOBORISK were applied.Results: 55 patients, 55% men and 45% women, there was statistical correlation between older age groups and PASI index (p=0.023). The main modifiable cardiovascular risk factors were smoking, sedentary lifestyle and obesity, statistical correlation was found for sedentary lifestyle (p=0.047). The main non-modifiable cardiovascular risk factors were Hypertension and Diabetes showing both statistical significance (p=0.004), (p=0.0001). The ATP-III criteria showed statistical significance for Hypertension, glycemia, total cholesterol and low HDL (p=0.003, p=0.008, p=0.027, p=0.017). The frequency of metabolic syndrome represented 47.27% of the sample. The most affected gender was male (61.54%). Statistical correlation was found in the older age groups for the presence of Metabolic Syndrome (p=0.0001). The group with the highest frequency of metabolic syndrome was the one with 6 to 10 years of the disease (p=0.001). When applying the Framingham and GLOBORISK scores, there were higher scores in the patients as PASI was increased. Conclusion:There is a higher frequency of Metabolic Syndrome in patients with Psoriasis, so it is recommended to establish measures aimed at reducing the burden of cardiovascular disease in these patients.

show abstract

Psoriasis Plays a Wild CARD

Cited by 3 publications

References 10 publications

Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis‐like histopathologic features

Interleukin 36 expression in psoriasis variants and other dermatologic diseases with psoriasis‐like histopathologic features

Association of CARD14 Single-Nucleotide Polymorphisms with Psoriasis

Comparative Stratification of Cardiovascular Risk through Framingham and Globo Risk in Patients with Psoriasis of IAHULA November 2017-May 2018

Contact Info

Product

Resources

About